Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $16.37 USD
Change Today -0.37 / -2.21%
Volume 150.8K
OSIR On Other Exchanges
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

osiris therapeutics inc (OSIR) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/19/15 - $18.86
52 Week Low
04/21/14 - $11.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

osiris therapeutics inc (OSIR) Related Businessweek News

No Related Businessweek News Found

osiris therapeutics inc (OSIR) Details

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix, a cryopreserved placental membrane for treating hard-to-treat acute and chronic wounds, venous leg ulcers, and burns; BIO4, a bone allograft for use in all surgical applications, including spine, trauma, extremity, cranial, and foot and ankle surgery; and Cartiform, a viable chondral allograft that promotes articular cartilage repair to treat focal chondral defects. It markets and distributes its products directly to hospitals, clinics, and physician offices as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

211 Employees
Last Reported Date: 03/20/15
Founded in 1992

osiris therapeutics inc (OSIR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $366.8K
Chief Financial Officer, Treasurer and Corpor...
Total Annual Compensation: $227.3K
Compensation as of Fiscal Year 2013.

osiris therapeutics inc (OSIR) Key Developments

Osiris Therapeutics, Inc. Promotes Alla Danilkovitch as Chief Scientific Officer

Osiris Therapeutics, Inc. announced the promotion of Alla Danilkovitch, Ph.D., to serve as Chief Scientific Officer. Dr. Danilkovitch has been with Osiris since 2003; her expertise and leadership has guided the company in the development of groundbreaking scientific ideas in regenerative medicine.

Stryker Spine and Stryker Trauma and Extremities to Launch Next Generation Viable Bone Matrix at the American Academy of Orthopaedic Surgeons

Stryker Corporation's Spine and Trauma & Extremities Divisions will be launching BIO4, the next generation viable bone matrix at booth #443 during the American Academy of Orthopaedic Surgeons Annual Meeting in Las Vegas, NV from March 24-28th. From the creators of the original allograft cellular bone matrix, Osiris Therapeutics, Inc., comes the next generation, BIO4, a viable bone matrix containing endogenous bone forming cells including mesenchymal stem cells, osteoprogenitor cells, osteoblasts, osteoinductive and angiogenic growth factors. BIO4 possesses all four characteristics involved in bone repair and regeneration: osteoconductive, osteoinductive, osteogenic and angiogenic. It is a safe alternative to bone autograft that minimizes the potential for harvest site co-morbidities. With the introduction of BIO4, Stryker now plays in the growing $199 million Cellular Allograft Market.

Osiris Therapeutics, Inc. announced delayed annual 10-K filing

On 03/17/2015, Osiris Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OSIR:US $16.37 USD -0.37

OSIR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $5.22 USD -0.21
Mesoblast Ltd A$3.79 AUD -0.04
Ocata Therapeutics Inc $6.98 USD -0.02
Organovo Holdings Inc $4.56 USD -0.16
Vitrolife AB kr155.00 SEK 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation OSIR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.4x
Price/Book 6.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OSIRIS THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at